Is it the ‘secret sauce’ in the cancer vaccine co-developed with Merck?
Adobe
Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77.Matthew Herper covers medical innovation — both its promise and its perils.Angus reports on the basic research, clinical science, and drug development that may transform survival and quality of life for patients, as well as developments affecting the cancer community. You can reach Angus on Signal at angus.08.
A personalized cancer vaccine developed by Moderna and Merck has generated widespread enthusiasm since the companies announced last week that it had succeeded in a late-stage trial. If regulators ultimately approve it, the treatment will be a triumph of immunology and cancer biology.
But it may also be a triumph of the algorithm.
